Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT00923897 : Palliative Radiotherapy (RT) for Liver Metastases (Mets) and Hepatocellular Carcinoma (HCC)(COLD 4)
PhasePhase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Patients with hepatocellular carcinoma or hepatic metastases from a solid malignancy,
unsuitable for radical therapy (including resection, transplant, conformal high dose
radiotherapy), confirmed by biopsy or imaging

- Symptoms of hepatic pain, discomfort, nausea, or fatigue requiring palliation

- KPS>60

- Expected survival of greater than 3 months

- Platelet count > 25 bil/L, Hemoglobin > 70 g/L, INR<3, Bilirubin<100 umol/L, AST <
350 U/L or ALT< 400 U/L

- Have signed an informed consent form approved by the Research Ethics Board (REB) at
Princess Margaret Hospital

Exclusion Criteria:

- Chemotherapy or novel drug within the past 2 weeks

- TACE(transarterial chemoembolization)within the past 1 month

- Plan for active treatment of the hepatocellular carcinoma or hepatic metastases,
including TACE or RFA or ETOH injection
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557